James Lind Centro de Investigación del Cáncer - Temuco
James Lind Centro de Investigación del Cáncer - Temuco
Hochstetter 298, Temuco
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Eduardo Yáñez Ruiz
Claudia Hernandez
Sebastian Arias
Mauro Morales Sanhueza
Patricio Yañez Weber
Tamara Ulloa
Open studies
Lung cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) - KEYVIBE-003 - Merck Sharp & Dohme Corp.See more
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Skin cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) - Merck Sharp & Dohme LLCSee more
Advanced tumors
Breast Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Colorectal cancer
A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) - Merck Sharp & Dohme LLCSee more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
Kidney cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Leukemia
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) - Merck Sharp & Dohme LLCSee more
Ovarian cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer - PROCLAIM 20170770 - Iqvia Rds ChileSee more
Solid tumors
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) - Merck Sharp & Dohme Corp.See more
